Track topics on Twitter Track topics that are important to you
KOL Perspectives: Perceptions of recent upcoming data for key HBV pipeline agents
This KOL Insight briefing focuses on KOLs views of recent upcoming data for key HBV pipeline agents.
Replicor's US trial plans and transition from IV to subcutaneous REP 2139
Efficacy of Spring Bank's inarigivir at 100mg in the Phase II ACHIEVE trial
Expected role for inarigivir in HBV
Efficacy of Arbutus's Q2W IV ARB1467
ARB1467, TDF + PegIFN trial design, potential for functional cure, regimen acceptability
Future development of Arbutus's nextgeneration RNAi therapeutic AB729For internal use only
Divided views on most relevant Phase I data required to differentiate RO7049389 from JNJ6379 ABIH0731, with most concluding that Phase I data is insufficien
KOLs agree Replicor is making positive steps towards REP 2139's development, but similar efficacy safety must be demonstrated in the US trials and for the SC formulation
Disagreement between US and EU KOLs over the improvement in efficacy of inarigivir at the 100mg dose.
The insight briefing is based on Sociable Pharma's analysis of primary research with our HBV key opinion leaders KOLs.
In total, we conducted interviews with 10 KOLs
5 Europebased 5 N. Americabased
Interviews performed during Sept 2018
KOL data is analyzed to produce
Charts summarizing KOL opinions
Chart callouts of key information details
Summary of KOL reporting trends
Insight from Sociable Pharma's analysts
Reasons to buy
Combines Qualitative semiquantitative insight from key opinion leaders on "recent upcoming data for key HBV pipeline agents"
Includes insight recommendations from our diseasespecific healthcare analysts
Utilizes independent expert viewpoints to validate the impact of new clinical data emerging trends on management of HBV
Provides costeffective support for your advisory boards, with topics acting as a catalyst for further expert discussion.NEXT ARTICLE
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...